2010
|
Sign up to set email alerts
A Case of Intravascular Large B-Cell Lymphoma With Atypical Clinical Manifestations and Analysis of CXCL12 and CXCR4 Expression
Search citation statements
Order By: Relevance
Paper Sections
Select...
11
4
1
0
Citation Types
0
9
0
0
Year Published
Range
2010
20102026
2026Publication Types
Select...
10
4
1
Relationship
0
15
Authors
Journals
Cited by 15 publications
(9 citation statements)
References 4 publications
0
9
0
0
Order By: Relevance
Smart CitationsHow the paper below cites the one you are viewing
“…33,34 These molecules are involved in the regulation of lymphocyte trafficking and integrin activation, 34 whereas the tumor-associated endothelial cells do not express their respective ligands (in particular Cxcl12 and, although more controversially, Cxcl9). 34,35 A number of homeostatic chemokine receptors such as Cxcr5, Ccr6, and Ccr7, which act on lymphocyte migration across vascular structures, 36 were consistently decreased in this lymphoma. 37 IVLBCL does not seem to express matrix metalloproteinase-2 and -9, 2 molecules important for parenchymal invasion.…”
Section: Pathogenesis
mentioning
confidence: 83%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…33,34 These molecules are involved in the regulation of lymphocyte trafficking and integrin activation, 34 whereas the tumor-associated endothelial cells do not express their respective ligands (in particular Cxcl12 and, although more controversially, Cxcl9). 34,35 A number of homeostatic chemokine receptors such as Cxcr5, Ccr6, and Ccr7, which act on lymphocyte migration across vascular structures, 36 were consistently decreased in this lymphoma. 37 IVLBCL does not seem to express matrix metalloproteinase-2 and -9, 2 molecules important for parenchymal invasion.…”
Section: Pathogenesis
mentioning
confidence: 83%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…They discovered that CXC chemokine receptors 3 and 4 (CXCR3 and CXCR4) are expressed in IVLBCL, as are their ligands, CXC chemokine ligands 9 and 12 (CXCL9 and CXCL12), and that the interaction of receptors and ligands causes tumor cell accumulation in the lumen of blood vessels. 47,48 Using next-generation sequencing, multiple researchers have discovered mutations in MYD88 and CD79B in IVLBCL. 49,50 We know that EBV drives the NF-κB signaling pathway to promote tumor growth, while lacks the cell surface proteins of lymphocytes across vascular endothelial cells, causing tumor cells to gather within the vascular lumen and become immobile.…”
Section: Discussion
mentioning
confidence: 99%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…Other than the generalized absence of adhesion molecules CD11b and CD18 16 , as well as the specific loss of CD29 and CD54 in CNS IVL 2 , very little is known about the molecular determinants of this malignancy. A few case reports described the presence of CXCL9 and CXCR3 17 , as well as CXCL12 and CXCR4 18 , on lymphoma cells and these CXC chemokines may serve as positive regulators for the lymphoma cells to aggregate in specific intravascular space. Vieites et al.…”
Section: Discussion
mentioning
confidence: 99%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…33,34 These molecules are involved in the regulation of lymphocyte trafficking and integrin activation, 34 whereas the tumor-associated endothelial cells do not express their respective ligands (in particular Cxcl12 and, although more controversially, Cxcl9). 34,35 A number of homeostatic chemokine receptors such as Cxcr5, Ccr6, and Ccr7, which act on lymphocyte migration across vascular structures, 36 were consistently decreased in this lymphoma. 37 IVLBCL does not seem to express matrix metalloproteinase-2 and -9, 2 molecules important for parenchymal invasion.…”
Section: Pathogenesis
mentioning
confidence: 83%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…They discovered that CXC chemokine receptors 3 and 4 (CXCR3 and CXCR4) are expressed in IVLBCL, as are their ligands, CXC chemokine ligands 9 and 12 (CXCL9 and CXCL12), and that the interaction of receptors and ligands causes tumor cell accumulation in the lumen of blood vessels. 47,48 Using next-generation sequencing, multiple researchers have discovered mutations in MYD88 and CD79B in IVLBCL. 49,50 We know that EBV drives the NF-κB signaling pathway to promote tumor growth, while lacks the cell surface proteins of lymphocytes across vascular endothelial cells, causing tumor cells to gather within the vascular lumen and become immobile.…”
Section: Discussion
mentioning
confidence: 99%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…Other than the generalized absence of adhesion molecules CD11b and CD18 16 , as well as the specific loss of CD29 and CD54 in CNS IVL 2 , very little is known about the molecular determinants of this malignancy. A few case reports described the presence of CXCL9 and CXCR3 17 , as well as CXCL12 and CXCR4 18 , on lymphoma cells and these CXC chemokines may serve as positive regulators for the lymphoma cells to aggregate in specific intravascular space. Vieites et al.…”
Section: Discussion
mentioning
confidence: 99%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…33,34 These molecules are involved in the regulation of lymphocyte trafficking and integrin activation, 34 whereas the tumor-associated endothelial cells do not express their respective ligands (in particular Cxcl12 and, although more controversially, Cxcl9). 34,35 A number of homeostatic chemokine receptors such as Cxcr5, Ccr6, and Ccr7, which act on lymphocyte migration across vascular structures, 36 were consistently decreased in this lymphoma. 37 IVLBCL does not seem to express matrix metalloproteinase-2 and -9, 2 molecules important for parenchymal invasion.…”
Section: Pathogenesis
mentioning
confidence: 83%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…They discovered that CXC chemokine receptors 3 and 4 (CXCR3 and CXCR4) are expressed in IVLBCL, as are their ligands, CXC chemokine ligands 9 and 12 (CXCL9 and CXCL12), and that the interaction of receptors and ligands causes tumor cell accumulation in the lumen of blood vessels. 47,48 Using next-generation sequencing, multiple researchers have discovered mutations in MYD88 and CD79B in IVLBCL. 49,50 We know that EBV drives the NF-κB signaling pathway to promote tumor growth, while lacks the cell surface proteins of lymphocytes across vascular endothelial cells, causing tumor cells to gather within the vascular lumen and become immobile.…”
Section: Discussion
mentioning
confidence: 99%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…Other than the generalized absence of adhesion molecules CD11b and CD18 16 , as well as the specific loss of CD29 and CD54 in CNS IVL 2 , very little is known about the molecular determinants of this malignancy. A few case reports described the presence of CXCL9 and CXCR3 17 , as well as CXCL12 and CXCR4 18 , on lymphoma cells and these CXC chemokines may serve as positive regulators for the lymphoma cells to aggregate in specific intravascular space. Vieites et al.…”
Section: Discussion
mentioning
confidence: 99%
Abstract